PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2023-02-14 (4)

Date Title Company
14-Feb-2023 Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Businesswire